Management of Acne in Transgender Men

Nicolas Kluger

Abstract

Acne is the most common dermatologic complication encountered by transgender men during the transition phase. It affects approximately 1 in 3 individuals, and they consider it severe in about 1 in 3 cases as well, mainly transgender men receiving testosterone. There are no specific recommendations for the management of acne in transgender patients but care generally follows the same approach as for cisgender patients. Prescribing isotretinoin is particular in transgender men because clinicians must inquire about their genital anatomy and sexual practices. Testosterone therapy and amenorrhea in a transgender man with native female reproductive organs do not eliminate the risk of pregnancy. Contraception with regular pregnancy testing may therefore be necessary.

References

1.
Winter, S.; Diamond, M.; Green, J.; et al. Transgender people: Health at the margins of society. Lancet 2016, 388, 390–400.
2.
Williams Institute at UCLA School of Law. New Estimate: 2.8 Million People Aged 13 and Older Identify as Transgender in the US. 2025. Available online: https://williamsinstitute.law.ucla.edu/press/trans-pop-estimates-press-release (accessed on 15 February 2026).
3.
Yeung, H.; Luk, K.M.; Chen, S.C.; et al. Dermatologic care for lesbian, gay, bisexual, and transgender persons: Terminology, demographics, health disparities, and approaches to care. J. Am. Acad. Dermatol. 2019, 80, 581–589.
4.
Yeung, H.; Luk, K.M.; Chen, S.C.; et al. Dermatologic care for lesbian, gay, bisexual, and transgender persons: Epidemiology, screening, and disease prevention. J. Am. Acad. Dermatol. 2019, 80, 591–602.
5.
Zouboulis, C.C.; Baron, J.M.; Böhm, M.; et al. Frontiers in sebaceous gland biology and pathology. Exp. Dermatol. 2008, 17, 542–551.
6.
Traupe, H.; von Mühlendahl, K.E.; Brämswig, J.; et al. Acne of the fulminans type following testosterone therapy in three excessively tall boys. Arch. Dermatol. 1988, 124, 414–417.
7.
Gao, J.L.; King, D.S.; Modest, A.M.; et al. Acne risk in transgender and gender diverse populations: A retrospective, comparative cohort study. J. Am. Acad. Dermatol. 2022, 87, 1198–1200.
8.
Smith, C.A.; Kaabi, O.; Manatunga, A.K.; et al. Acne incidence and severity in transgender individuals. JAMA Dermatol. 2026, 162, 255–263.
9.
Imhof, R.L.; Davidge-Pitts, C.J.; Miest, R.Y.N.; et al. Dermatologic disorders in transgender patients: A retrospective cohort of 442 patients. J. Am. Acad. Dermatol. 2020, 83, 1516–1518.
10.
Seibert, D.; Cohen, L.N.; Boswell, N.; et al. Acne in transmasculine patients: A scoping review. JAMA Dermatol. 2026, 162, 66–71.
11.
Park, J.A.; Carter, E.E.; Larson, A.R. Risk factors for acne development in the first 2 years after initiating masculinizing testosterone therapy among transgender men. J. Am. Acad. Dermatol. 2019, 81, 617–618.
12.
Thoreson, N.; Park, J.A.; Grasso, C.; et al. Incidence and factors associated with acne among transgender patients receiving masculinizing hormone therapy. JAMA Dermatol. 2021, 157, 290–295.
13.
Radi, R.; Gold, S.; Acosta, J.P.; et al. Treating acne in transgender persons receiving testosterone: A practical guide. Am. J. Clin. Dermatol. 2022, 23, 219–229.
14.
Yeung, H.; Ragmanauskaite, L.; Zhang, Q.; et al. Prevalence of moderate to severe acne in transgender adults: A cross-sectional survey. J. Am. Acad. Dermatol. 2020, 83, 1450–1452.
15.
Braun, H.; Zhang, Q.; Getahun, D.; et al. Moderate-to-severe acne and mental health symptoms in transmasculine persons who have received testosterone. JAMA Dermatol. 2021, 157, 344–346.
16.
Lee, G.; Ferri-Huerta, R.; Greenberg, K.B.; et al. Acne fulminans in a transgender boy after an increase in testosterone dosage. JAAD Case Rep. 2022, 21, 32–34.
17.
Peitzmeier, S.; Gardner, I.; Weinand, J.; et al. Health impact of chest binding among transgender adults: A community-engaged, cross-sectional study. Cult. Health Sex. 2017, 19, 64–75.
18.
Auffret, N.; Ballanger, F.; Leccia, M.T.; et al. Acne in transgender patients: Disease management and treatment recommendations from a group of experts on acne. Eur. J. Dermatol. 2024, 34, 609–615.
19.
Reynolds, R.V.; Yeung, H.; Cheng, C.E.; et al. Guidelines of care for the management of acne vulgaris. J. Am. Acad. Dermatol. 2024, 90, 1006.e1–1006.e30.
20.
Campos-Muñoz, L.; López-De Lara, D.; Rodríguez-Rojo, M.L.; et al. Transgender adolescents and acne: A case series. Pediatr. Dermatol. 2018, 35, e155–e158.
21.
Kircik, L.H. Androgens and acne: Perspectives on clascoterone, the first topical androgen receptor antagonist. Expert Opin. Pharmacother. 2021, 22, 1801–1806.
22.
ACOG. Health Care for Transgender and Gender Diverse Individuals. 2021. Available online: https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2021/03/health-care-for-transgender-and-gender-diverse-individuals (accessed on 15 February 2026).
23.
Richer, V.; Kuritzky, L.A. Considerations in treating severe acne with isotretinoin in transgender men. J. Cutan. Med. Surg. 2020, 24, 529–530.
24.
Light, A.D.; Obedin-Maliver, J.; Sevelius, J.M.; et al. Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstet. Gynecol. 2014, 124, 1120–1127.
25.
Kuritzky, L.A.; Richer, V. Response to reader comment on “Considerations in treating severe acne with isotretinoin in transgender men”. J. Cutan. Med. Surg. 2021, 25, 340–341.
26.
Yeung, H.; Chen, S.C.; Katz, K.A.; et al. Prescribing isotretinoin in the United States for transgender individuals: Ethical considerations. J. Am. Acad. Dermatol. 2016, 75, 648–651.
27.
Campos-Muñoz, L.; López-De Lara, D.; Conde-Taboada, A.; et al. Depression in transgender adolescents under treatment with isotretinoin. Clin. Exp. Dermatol. 2020, 45, 615–616.
28.
Tan, N.K.W.; Tang, A.; MacAlevey, N.C.Y.L.; et al. Risk of suicide and psychiatric disorders among isotretinoin users: A meta-analysis. JAMA Dermatol. 2024, 160, 54–62.

Scilight Press

Author Information

Abstract

Keywords

References

About Scilight

Journals

Publishing Policies

Contact Us